Serum soluble CD25 (sCD25) is an indicator for rheumatoid arthritis-associated interstitial lung disease
Authors' conclusion
sCD25 was significantly elevated in RA-ILD (including UIP, NSIP and RA-ILA) compared to RA-no-ILD and HCs
Study context
- Population
- Rheumatoid arthritis (RA) patients, discovery cohort (15 with interstitial lung disease (ILD), 57 without ILD) and validation cohort (41 with ILD, 181 without ILD), and healthy controls
- Participants
- 294 RA patients
- Comparison
- Serum sCD25 in RA with ILD vs RA without ILD and healthy controls
- Healthy controls (HCs)n = 58
- Outcome
- Serum sCD25 concentration (enzyme-linked immunosorbent assay (ELISA)) and its association with RA-ILD
Methodological detailsdiscovery cohort, validation cohort
- Discovery cohort
- Validation cohort
Performance
As reported in the abstract
Serum sCD25, RA-ILD vs RA-no-ILD (discovery cohort)
| Test or model | AUC |
|---|---|
| RA-ILD | 0.695 |
RA-ILD
AUC0.695
- RA-ILD vs RA-no-ILD: P = 0.004 — sCD25 significantly higher in RA-ILD
- AUC 95% CI
- 0.541-0.849
Further findings
| Outcome | RA-ILD | P value |
|---|---|---|
| Serum sCD25, RA-ILD vs RA-no-ILD (validation cohort)Result confirmed in validation cohort | P < 0.001 | |
| Sensitivity | 51.2% | |
| Specificity | 77.3% |
- sCD25 by high-resolution computed tomography (HRCT) pattern (UIP, NSIP, RA-ILA) vs RA-no-ILD — sCD25 higher in UIP, NSIP and RA-ILA than RA-no-ILD
- p<0.05
- Serum sCD25, RA-ILD vs RA-no-ILD (validation cohort): sensitivity and specificity by discovery-cohort cut-off value
- sCD25 by HRCT pattern (UIP, NSIP, RA-ILA) vs RA-no-ILD: UIP AUC 0.730
- sCD25 by HRCT pattern (UIP, NSIP, RA-ILA) vs RA-no-ILD: NSIP AUC 0.761
- sCD25 by HRCT pattern (UIP, NSIP, RA-ILA) vs RA-no-ILD: RA-ILA AUC 0. 694
sCD25 and HRCT findings
- sCD25 not correlated with HRCT scores
- sCD25 significantly higher in consolidation pattern
Original publication
Serum sCD25 is an indicator for rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol. Published 21 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →